Ultimately, the risk of peripheral neuropathy increased by an estimated 3% for each additional day of current fluoroquinolone exposure, maintained for up to 180 days post-exposure.
Drs Ronald C. Petersen and Alireza Atri provide a historical overview on the management of Alzheimer disease and comment on the likelihood of seeing new therapy emerge for the condition in the near future.

SAP Partner Banner